Niacin In Patients With Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 3196 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
The addition of time release niacin (1,500-2,000mg) daily for two years with one year followup alongside statin therapy, compared to statin therapy alone, improved biomarkers of cardiovascular health (LDL, HDL, triglycerides by 12%, 25%, and 28.6% respectively) but failed to reduce the risk of cardiovascular events such as ischemic stroke or myocardial infarction any more than statins alone.Funding issues for this study:
Other biomarkers that were not elaborated on, Apolipoproteins A1 and B as well as lipoprotein(a), did not appear to be significantly influenced; no measurements were taken of these at the end of two years, just after 1 and 3 years (for the apolipoproteins) or after 1 year (lipoprotein(a))
Study conducted with a Grant from Abbott labratories; Niacin donated from Abbott and Simvastatin from Merck
